Germany’s IQWiG Downs Two Drugs In One Day
This article was originally published in The Pink Sheet Daily
Executive Summary
IQWiG turned down both GSK/Valeant’s Trobalt and Novartis’ Rasilamlo for lack of evidence of added benefit, after manufacturers’ choice of comparator deviated from those selected by the G-BA.
You may also be interested in...
Reversal Of Fortune For German Pharma As Bundesrat Supports Enhanced Drug Price Transparency
Germany’s upper house of parliament, the Bundesrat, has decided after considerable wrangling that negotiated and discounted reimbursement prices of drugs sold in Europe’s biggest market will be made public, virtually ensuring that further price erosion will spread across the region.
German Pharma Industry Cries Foul As Preliminary Evaluation Of AMNOG Suggests It Works
Germany’s powerful health care watchdog G-BA, in its first full opinion on early added benefit assessment of medicines, says the process is fair and promotes real drug innovation, in sharp contrast to the biopharma industry which maintains it is a cost-cutting tool wielded by health insurance funds.
Specialty Pharma Dominates Epilepsy Market, But Does It Have Resources To Develop Disease-Modifying Agents?
Upsher-Smith’s recent acquisition of research boutique Proximagen highlights the dynamics of the market: specialty pharma extending dominance and introducing new agents to the market, while most early R&D activity originates at small firms. But it may be difficult for this combination of players to bring forth the game-changing therapies that are needed, given the technical challenges of the disease space.